Skip to content

Effectiveness and cost-effectiveness of sacral neuromodulation in patients with idiopathic slow-transit constipation refractory to conservative treatment

Effectiveness and cost-effectiveness of sacral neuromodulation in patients with idiopathic slow-transit constipation refractory to conservative treatment - SNM for constipation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50732
Enrollment
67
Registered
2016-06-15
Start date
2017-02-21
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation slow-transit constipation

Interventions

The intervention is SNM, a minimally invasive surgical procedure consisting of two phases. In the screening phase an electrode is inserted near the third sacral nerve and connected to an external st

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: - An average defecation frequency (DF) of

Exclusion criteria

Exclusion criteria: * Obstructed outlet syndrome (objectified by defeacography) * Irritable bowel syndrome (Rome-IV criteria for irritable bowel syndrome) * Congenital or organic bowel pathology * Rectal prolapse * Anatomical limitations preventing placement of an electrode * Skin and perineal disease with risk of infection * Previous large bowel/rectal surgery * Stoma * Coexisting neurological disease * Significant psychological co-morbidity as assessed subjectively by the investigator * Being or attempting to become pregnant during study follow-up

Design outcomes

Primary

MeasureTime frame
The main outcome is treatment success. Patients with an average defecation frequency (DF) of *3 a week are considered successfully treated. Patients with an average DF of

Secondary

MeasureTime frame
* Proportion of patients with a 50% reduction in the proportion of defecations with straining, derived from the defecation diary. * Proportion of patients with a 50% reduction in the proportion of defecations with a sense of incomplete evacuation, derived from the defecation diary * Constipation severity, displayed with the score from the Wexner constipation score (WCS). * Fatigue, displayed with the score from the *Verkorte vermoeidheidsvragenlijst* (VVV) * Constipation-specific (health-related) quality of life ((HR)QOL), displayed with the score from the Patient Assessment of Constipation * Quality of Life (PAC-QOL) questionnaire. * Generic (HR)QOL, measured with the EQ-5D-5L, the ICECAP-A (adults) and the KIDSCREEN-27 (adolescents) * Adverse events/complications, reported by the clinician in a case report form (CRF) * Resource use/costs from a societal and health care perspective * Cost-effectiveness from a societal and health care perspective * Budget-impact from a societal, health care and health care insurance perspective

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)